ENTX

Entera Bio Ltd.

8 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 8

Secured $10 million via private placement from BVF Partners to extend runway.

capital raise

70%

bearishMay 8

Net loss increased 37% year-over-year to $3.5 million.

earnings miss

60%

bearishMay 8

R&D expenses doubled year-over-year due to increased clinical trial costs.

margin compression

50%

bullishMay 8

Secured $10 million via private placement from BVF Partners to extend runway.

capital raise

70%

bearishMay 8

Net loss increased 37% year-over-year to $3.5 million.

earnings miss

60%

bearishMay 8

R&D expenses doubled year-over-year due to increased clinical trial costs.

margin compression

50%

bullishMay 8

Secured $10 million via private placement from BVF Partners to extend runway.

capital raise

70%

bearishMay 8

Net loss increased 37% year-over-year to $3.5 million.

earnings miss

60%

bearishMay 8

R&D expenses doubled year-over-year due to increased clinical trial costs.

margin compression

50%

bullishMay 8

Secured $10 million via private placement from BVF Partners to extend runway.

capital raise

70%

bearishMay 8

Net loss increased 37% year-over-year to $3.5 million.

earnings miss

60%

bearishMay 8

R&D expenses doubled year-over-year due to increased clinical trial costs.

margin compression

50%

bullishMay 8

Secured $10 million via private placement from BVF Partners to extend runway.

capital raise

70%

bearishMay 8

Net loss increased 37% year-over-year to $3.5 million.

earnings miss

60%

bearishMay 8

R&D expenses doubled year-over-year due to increased clinical trial costs.

margin compression

50%

bullishMay 8

Secured $10 million via private placement from BVF Partners to extend runway.

capital raise

70%

bearishMay 8

Net loss increased 37% year-over-year to $3.5 million.

earnings miss

60%

bearishMay 8

R&D expenses doubled year-over-year due to increased clinical trial costs.

margin compression

50%

bullishMay 8

Secured $10 million via private placement from BVF Partners to extend runway.

capital raise

70%

bearishMay 8

Net loss increased 37% year-over-year to $3.5 million.

earnings miss

60%

bearishMay 8

R&D expenses doubled year-over-year due to increased clinical trial costs.

margin compression

50%

bullishMar 27

FDA qualification of total hip BMD as a surrogate endpoint accelerates the path to NDA.

regulatory action

90%

bearishMar 27

Insufficient cash to fund Phase 3 trials necessitates additional capital raises.

dilution risk

80%

bullishMar 27

Expanded strategic collaboration with OPKO Health for LA-PTH and OXM programs.

acquisition

60%

Filing History

10-QMay 8, 2026

The Q1 2026 filing reveals a company at a critical inflection point, balancing high-potential clinical catalysts against a fragile balance sheet. While the submission of the EB613 Phase 3 protocol and the expansion of the OPKO collaboration provide a clear path toward value creation, the 'going concern' warning serves as a stark reminder of the capital intensity of biotech development. The recent $10 million raise provides temporary relief, but the company's survival depends on its ability to secure significantly more funding to execute its pivotal trials. Ultimately, Entera Bio is a high-risk, high-reward play on the N-Tab platform's ability to deliver oral versions of previously injectable peptides. The market's valuation will likely hinge on the successful initiation of the Phase 3 study in the second half of 2026 and the company's ability to attract institutional capital without excessive dilution. The synthesis of this filing suggests a race against time where clinical success must outpace the depletion of cash reserves.

10-KMar 27, 2026

The 10-K filing presents a company at a critical inflection point where scientific validation clashes with financial fragility. On one hand, the FDA's acceptance of BMD as a surrogate endpoint is a transformative win that streamlines the path to market for EB613. On the other, the 'going concern' warning from independent auditors highlights a desperate need for capital. The tension between these two forces—regulatory acceleration and financial depletion—will define the stock's trajectory in the coming quarters. Ultimately, Entera's value proposition rests on the successful execution of the Phase 3 protocol submitted in February 2026. While the N-Tab platform offers immense optionality in the GLP-1 and hypoparathyroidism spaces, the immediate priority is surviving the liquidity crunch. Investors are essentially betting that the regulatory shortcut provided by the FDA will attract enough strategic interest or capital to fund the final stretch to commercialization without wiping out existing equity holders.